Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...

Shares in Pfizer ($PFE) inched higher early Tuesday even as the U.S. pharma giant forecast 2026 earnings that are below Wall ...

Pfizer shares fall after a muted 2026 outlook, with projected modest revenue growth, lower COVID sales and deal dilution weighing on investor sentiment.

Pfizer PFE recently announced a landmark deal with the Trump administration. Per the deal, Pfizer committed to key measures aimed at lowering prescription drug costs while boosting investment in ...

Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ...

Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped ...

As of the close of business on December 5, around 60% of the 26 Wall Street analysts with recommendations on Pfizer have a Hold rating for the stock. The pharmaceuticals company has a one-year average ...

SureCare Pharmacy manager Oscar Uribe shows off a package of Pfizer Paxlovid pills inside of Esperanza Health Center in Chicago on Jan. 13, 2022. Pfizer's Paxlovid is a treatment for COVID-19. (Chris ...

Market pessimism creates opportunity. Pfizer and Rexford Industrial trade at historically low valuations, offering high dividend yields and strong long-term growth potential. Pfizer's diversified drug ...